Comparative Pharmacology
Head-to-head clinical analysis: ALVESCO versus AZMACORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALVESCO versus AZMACORT.
ALVESCO vs AZMACORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ciclesonide is a prodrug that is converted to the active metabolite des-ciclesonide, which has anti-inflammatory activity by binding to glucocorticoid receptors, thereby inhibiting inflammatory mediators such as cytokines and leukotrienes.
Corticosteroid that binds to glucocorticoid receptors, modulating gene transcription to produce anti-inflammatory and immunosuppressive effects.
Inhalation: 160 mcg twice daily (morning and evening). May be increased to 320 mcg twice daily if inadequate response. Maximum 640 mcg twice daily.
Two inhalations (200 mcg) three to four times daily or four inhalations (400 mcg) twice daily via oral inhalation.
None Documented
None Documented
Terminal elimination half-life is approximately 2-3 hours for the systemically absorbed fraction; however, the receptor occupancy half-life is significantly longer due to lipophilic tissue binding, providing therapeutic duration of 12 hours.
Terminal elimination half-life of 3-4 hours for the inhaled route; prolonged in hepatic impairment.
Primarily hepatic metabolism (CYP3A4) to less active metabolites; renal excretion accounts for <10% unchanged; fecal excretion as metabolites ~80%.
Primarily fecal (60-80%) and renal (10-20%) as metabolites; unchanged drug <5% in urine.
Category C
Category C
Inhaled Corticosteroid
Inhaled Corticosteroid